{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xu J"],"funding":["NCI NIH HHS","University of Texas Medical Branch","National Institutes of Health"],"pagination":["114229"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9040195"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["234"],"pubmed_abstract":["In our continued SAR study efforts, a series of O-alkylamino-tethered salicylamide derivatives with various amino acid linkers has been designed, synthesized, and biologically evaluated as potent anticancer agents. Five selected compounds with different representative chemical structures were found to show broad anti-proliferative activities, effective against all tested ER-positive breast cancer (BC) and triple-negative breast cancer (TNBC) cell lines with low micromolar IC<sub>50</sub> values. Among these compounds, compound 9a (JMX0293) maintained good potency against MDA-MB-231 cell line (IC<sub>50</sub> = 3.38 ± 0.37 μM) while exhibiting very low toxicity against human non-tumorigenic breast epithelial cell line MCF-10A (IC<sub>50</sub> > 60 μM). Further mechanistic studies showed tha"],"journal":["European journal of medicinal chemistry"],"pubmed_title":["Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents."],"pmcid":["PMC9040195"],"funding_grant_id":["R01 CA226001","R01CA226001","R01CA231150","R01 CA231150"],"pubmed_authors":["Zhou M","Ma R","Shen Q","Kim H","Dong J","Wang T","Chen H","Xu J","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Structure-activity relationship studies on O-alkylamino-tethered salicylamide derivatives with various amino acid linkers as potent anticancer agents.","description":"In our continued SAR study efforts, a series of O-alkylamino-tethered salicylamide derivatives with various amino acid linkers has been designed, synthesized, and biologically evaluated as potent anticancer agents. Five selected compounds with different representative chemical structures were found to show broad anti-proliferative activities, effective against all tested ER-positive breast cancer (BC) and triple-negative breast cancer (TNBC) cell lines with low micromolar IC<sub>50</sub> values. Among these compounds, compound 9a (JMX0293) maintained good potency against MDA-MB-231 cell line (IC<sub>50</sub> = 3.38 ± 0.37 μM) while exhibiting very low toxicity against human non-tumorigenic breast epithelial cell line MCF-10A (IC<sub>50</sub> > 60 μM). Further mechanistic studies showed tha","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-21T22:59:43.267Z","creation":"2025-04-05T18:58:46.458Z"},"accession":"S-EPMC9040195","cross_references":{"pubmed":["35334447"],"doi":["10.1016/j.ejmech.2022.114229"]}}